Skip to main content
. Author manuscript; available in PMC: 2023 Apr 25.
Published in final edited form as: Gastroenterology. 2022 May 24;163(3):659–670. doi: 10.1053/j.gastro.2022.05.029

Figure 2.

Figure 2.

CD-specific aGMAbs precede the onset of disease by years. (A) and (B) show reciprocal titers of aGMAbs (IgG and IgA) in combined serum samples (training and validation cohort) at 2 time points before and 1 time point after diagnosis. (C) Trajectory of aGMAb titers in patients with CD. Blue lines indicate aGMAb+, black lines aGMAb− patients, and red lines indicate sero-converters. (D) Kaplan-Meier analysis with hazard ratio for developing complications after diagnosis in aGMAb+ (red) and aGMAb− patients 6 years before disease. (E) Correlations of aGMAb with anti-saccharomyces cerevisiae antibodies (ASCA) IgG and ASCA IgA antibodies at different time points before diagnosis. (F) Clusters of SOMAmers correlating with aGMAbs before (d-2175) and after (d+100) diagnosis of CD.